Pharvaris (NASDAQ:PHVS - Get Free Report)'s share price traded down 8.4% during trading on Monday . The company traded as low as $13.13 and last traded at $13.08. 4,997 shares changed hands during trading, a decline of 93% from the average session volume of 71,812 shares. The stock had previously closed at $14.28.
Wall Street Analyst Weigh In
Separately, JMP Securities increased their target price on Pharvaris from $46.00 to $55.00 and gave the company a "market outperform" rating in a report on Friday, January 31st.
Get Our Latest Stock Report on Pharvaris
Pharvaris Price Performance
The company's 50-day simple moving average is $15.55 and its two-hundred day simple moving average is $18.36. The firm has a market capitalization of $627.48 million, a P/E ratio of -4.29 and a beta of -2.84.
Pharvaris (NASDAQ:PHVS - Get Free Report) last released its earnings results on Monday, April 7th. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.06. Analysts predict that Pharvaris will post -2.71 earnings per share for the current year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Public Employees Retirement System of Ohio purchased a new position in Pharvaris during the third quarter valued at $57,000. JPMorgan Chase & Co. grew its holdings in shares of Pharvaris by 1,125.3% in the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock valued at $59,000 after purchasing an additional 2,847 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in Pharvaris in the fourth quarter worth $64,000. Barclays PLC bought a new position in Pharvaris during the third quarter valued at $106,000. Finally, KLP Kapitalforvaltning AS purchased a new position in shares of Pharvaris in the 4th quarter worth $111,000.
Pharvaris Company Profile
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Read More
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
